Literature DB >> 12614417

Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients.

M Isabel Longo1, Pablo Lázaro, Celso Bueno, José Luis Carreras, Ricardo Montz.   

Abstract

BACKGROUND: Positron emission tomography (PET) imaging is superior to conventional techniques for the evaluation of patients with stage III and stage IV cutaneous melanoma. Several studies have highlighted the advantages of this noninvasive technique for the assessment of lymph node involvement.
OBJECTIVE: To compare PET imaging with sentinel node biopsy for primary staging of cutaneous melanoma and to discuss the technical limitations of PET scanning.
METHODS: Twenty-five consecutive patients with a histologic diagnosis of melanoma with a Breslow thickness equal or greater to 1 mm underwent a preoperative PET to assess lymph node involvement.
RESULTS: Sentinel node biopsy and PET showed a sensitivity of 100% and 22%, respectively, in the identification of lymph node metastases.
CONCLUSION: PET is not a sensitive technique for the primary staging of cutaneous melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614417     DOI: 10.1046/j.1524-4725.2003.29058.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  9 in total

1.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.

Authors:  Yan Xing; Yulia Bronstein; Merrick I Ross; Robert L Askew; Jeffrey E Lee; Jeffrey E Gershenwald; Richard Royal; Janice N Cormier
Journal:  J Natl Cancer Inst       Date:  2010-11-16       Impact factor: 13.506

2.  Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy.

Authors:  Janne Horn; Jørgen Lock-Andersen; Helle Sjøstrand; Annika Loft
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-04       Impact factor: 9.236

Review 3.  F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.

Authors:  Milly A Schröer-Günther; Robert F Wolff; Marie E Westwood; Fülöp J Scheibler; Christoph Schürmann; Brigitta G Baumert; Stefan Sauerland; Jos Kleijnen
Journal:  Syst Rev       Date:  2012-12-13

4.  Comparison between F-Fluorodeoxyglucose Positron Emission Tomography and Sentinel Lymph Node Biopsy for Regional Lymph Nodal Staging in Patients with Melanoma: A Review of the Literature.

Authors:  Paoletta Mirk; Giorgio Treglia; Marco Salsano; Pietro Basile; Alessandro Giordano; Lorenzo Bonomo
Journal:  Radiol Res Pract       Date:  2011-12-22

5.  Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma.

Authors:  Rodrigo Arrangoiz; Pavlos Papavasiliou; Carrie A Stransky; Jian Q Yu; Li Tianyu; Elin R Sigurdson; Adam C Berger; Jeffrey M Farma
Journal:  Dermatol Res Pract       Date:  2012-05-13

6.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

7.  Selective targeting of melanoma using N-(2-diethylaminoethyl) 4-[18F]fluoroethoxy benzamide (4-[18F]FEBZA): a novel PET imaging probe.

Authors:  Pradeep K Garg; Rachid Nazih; Yanjun Wu; Vladimir P Grinevich; Sudha Garg
Journal:  EJNMMI Res       Date:  2017-08-08       Impact factor: 3.138

8.  Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.

Authors:  Felisa Jiménez-Requena; Roberto C Delgado-Bolton; Cristina Fernández-Pérez; Sanjiv S Gambhir; Judy Schwimmer; José M Pérez-Vázquez; José L Carreras-Delgado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-02       Impact factor: 9.236

9.  Malignant melanoma.

Authors:  Aída Ortega Candil; Cristina Rodríguez Rey; José Luis Carreras Delgado
Journal:  ISRN Dermatol       Date:  2012-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.